Murray N, Lyons J, Layton C, Balcon R
Br Heart J. 1987 Feb;57(2):144-7. doi: 10.1136/hrt.57.2.144.
Four hundred and three patients were considered for entry into a trial of intravenous streptokinase in suspected myocardial infarction. Three hundred and sixty seven (91%) were excluded. Two hundred and sixty (65%) did not meet the inclusion criteria and 45 of the remaining 143 (35%) patients had contraindications to thrombolysis. This left 98 (24%) patients who were suitable for thrombolysis and 42 of them were over 70 years, the upper age limit. Thus according to this trial protocol 56 (14%) patients were eligible for recruitment; 36 (9%) patients were finally randomised. These data suggest that treatment with intravenous streptokinase may be applicable to only a small proportion of patients with myocardial infarction.
403名患者被考虑纳入疑似心肌梗死静脉注射链激酶的试验。367名（91%）被排除。260名（65%）不符合纳入标准，其余143名患者中有45名（35%）有溶栓禁忌症。这使得98名（24%）患者适合溶栓，其中42名年龄超过70岁这一年龄上限。因此，根据该试验方案，56名（14%）患者符合招募条件；最终36名（9%）患者被随机分组。这些数据表明，静脉注射链激酶治疗可能仅适用于一小部分心肌梗死患者。
